MICs were determined using an agar dilution technique. 
Introduction
Colistin has been available since the early 1960s for the treatment of infections caused by Gram-negative organisms. In common with other polymixins, colistin is rapidly bactericidal and exerts its effects by acting as a cationic detergent, causing disruption of the integrity of the bacterial cell membrane, with leakage of intracellular contents and cell death. This process is not dependent upon bacterial metabolic activity 1 and may be a significant contributing factor to the lack of development of bacterial resistance to colistin. Although its use as parenteral therapy has been limited due to concerns about toxicity, colistin has nevertheless been extensively used, for example, as inhaled therapy for the treatment of infection by Pseudomonas aeruginosa in patients with cystic fibrosis, 2 as part of antibiotic regimens for selective decontamination of the digestive tract, 3 and in preparations for topical and ophthalmic use.
The increasing incidence of infections caused by organisms with resistance mechanisms to many of the more commonly prescribed antimicrobial agents has prompted a review of the activity of older compounds (as well as adding some urgency to the search for new ones). In this study, the in-vitro activity of colistin sulphomethate sodium was compared with those of other antimicrobial agents, including the newer antibiotics cefpirome and meropenem, against a range of clinical isolates of Enterobacteriaceae and P. aeruginosa, and other laboratory strains with characterized resistance patterns.
Materials and methods
A total of 377 recent clinical isolates (including 94 strains of P. aeruginosa from patients with cystic fibrosis), NCTC control organisms (P. aeruginosa 10662 and Escherichia coli 10418) and organisms with known mechanisms of resistance were tested. Colistin sulphomethate sodium was obtained from Pharmax (Bexley, UK), ciprofloxacin and azlocillin from Bayer AG (Leverkusen, Germany), meropenem from Zeneca Pharmaceuticals (Macclesfield, UK), imipenem from Merck Sharpe & Dohme Ltd (Hoddesdon, UK), cefpirome from Hoechst-Roussel Ltd (Uxbridge, UK), ceftazidime and cefuroxime from Glaxo Laboratories Ltd (Greenford, UK) and amoxycillin and clavulanic acid from SmithKline Beecham (Welwyn Garden City, UK). 1 0 4 cfu. After incubation for 18-24 h at 35-37°C in air, plates were examined for growth. The MIC of the antibiotic was defined as the concentration at which growth was inhibited (one or two colonies were ignored).
Results and discussion
Results for the NCTC strains were within one dilutional step of the expected MICs of all the antimicrobials tested (data not shown). The antimicrobial activities of colistin and the other agents against the clinical strains are shown in Table I . Against the 94 strains of P. aeruginosa, colistin displayed useful activity (MIC 90 4 mg/L), although it was two to four times less active than ciprofloxacin, meropenem or imipenem. Four strains of P. aeruginosa that were fully resistant to ceftazidime remained susceptible to colistin (MIC 2-4 mg/L). The MIC of colistin for one strain of P. aeruginosa was 32 mg/L. All the other agents tested except cefpirome (MIC 16 mg/L) were active against this strain. The activity of colistin was generally greater than that of either azlocillin or cefpirome.
All 50 clinical strains of E. coli were susceptible to colistin, although cefpirome, imipenem and meropenem were up to eight times more active. Colistin was, however, considerably more active than amoxycillin (MIC 90 128 mg/L), co-amoxiclav and cefuroxime. There was no useful activity demonstrated against Providentia spp. or Serratia spp., and one-third of the strains of Enterobacter spp. tested were not inhibited by colistin 4 mg/L. These strains were all highly susceptible to cefpirome, ceftazidime, ciprofloxacin, imipenem and meropenem, whilst amoxycillin, co-amoxiclav and cefuroxime had little or no activity. Acinetobacter spp., Citrobacter spp. and Klebsiella spp. were all generally susceptible to colistin (MIC 90 s 2, 1 and 8 mg/L, respectively), which was more active than amoxycillin and the cephalosporins, but less so than imipenem and meropenem. All the enteric pathogen strains (Shigella spp. and S a l m o n e l l a spp.) were inhibited by colistin 2 mg/L; amoxycillin, co-amoxiclav and azlocillin were several-fold less active.
Antimicrobial activity against strains with characterized resistance mechanisms is shown in Table II . Colistin activity was well preserved against all the transconjugant strains possessing known -lactamases (TEM-1, TEM-2, TEM-3, TEM-6, TEM-7, TEM-9, TEM-10, SHV-1, SHV-2, SHV-3, P99, K1). Of the cephalosporins, cefpirome remained the most active against these strains, and the carbapenems were highly active (data not shown). The strains of Klebsiella pneumoniae displaying resistance to norfloxacin and enoxacin also showed decreased susceptibility to ciprofloxacin (MIC 2-8 mg/L). No cross-resistance to colistin was detected in any of these characterized strains.
The results of this study are in broad agreement with other published data, 5, 6 and confirm that colistin has maintained useful in-vitro activity against the Enterobacteriaceae (with the exception of Providentia spp. and Serratia spp.) and P. aeruginosa. Overall, however, colistin was not as active as imipenem or meropenem against the range of organisms studied, but compared favourably with ceftazidime, cefpirome and ciprofloxacin. In contrast, azlocillin, amoxycillin (co-amoxiclav) and cefuroxime were considerably less active. The Working Party on Antibiotic Sensitivity Testing of the BSAC has recently recommended a breakpoint concentration of 4 mg/L for colistin (J. Andrews, personal communication), a level readily achievable in serum following iv administration.
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Most of the strains tested in this study were susceptible to concentrations of colistin at or below this level, and the findings reported here support such a recommended breakpoint. Parenteral therapy with colistin has frequently been associated with adverse events. Toxicity appears to be related to drug formulation (colistin sulphate is more toxic than the methane sulphonate form) and dose (related to renal function and body weight). Nephrotoxicity has been reported in up to 20% of courses, and neurotoxicity, including dizziness and nausea, peripheral neuropathy, neuromuscular blockade, convulsions and coma, in around 7% of courses. 8 However, this reputation for toxicity has recently been questioned. 7, 9 Colistin should not be used to treat minor infections or infections in which the infecting organism is susceptible to other less toxic agents. However, the useful activity of this antibiotic against bacteria resistant to other agents suggests that colistin may have an important role to play in the treatment of serious infections with these strains. 
